Abstract

Disclosed is a pharmaceutical composition for treating immunological disorders by inhibiting the activation of T lymphocytes, comprising, as active ingredients, two or more selected from the group consisting of a substance capable of blocking binding of an MHC (Major Histocompatibility Complex) Class II molecule and a receptor thereof, a substance capable of blocking binding of an adhesion molecule and a receptor thereof, a substance capable of blocking binding of an adhesion molecule and a receptor thereof, and a substance capable of blocking binding of a cytokine and a receptor thereof.

5